EXELIXIS, INC. — fact timeline

Source-grounded facts extracted from EXELIXIS, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.

Earnings Releases May 5, 2026, 7:59 PM ET

EXELIXIS, INC. reported first quarter of 2026 results: revenue $610.8 million, net income $210.5 million, EPS $0.79 per share, diluted.

“& Investor Relations Exelixis, Inc. 650-837-7248 apeters@exelixis.com Exelixis Announces First Quarter 2026 Financial Results and Provides Corporate Update - Total Revenues of $610.8 million, Cabozantinib Franchise U.S. Net Product Revenues of $555.0 million - - GAAP Diluted EPS of $0.79, Non-GAAP Diluted EPS of $0.87 - - Announced Additional Stock Repurchase Program”

Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.